The clinical impact of cyclosporine nephrotoxicity in heart transplantation

Transplantation

Volumn 69, Issue 12 SUPPL., 2000, Pages

  Parry, Gareth ^a   Meiser, Bruno ^a   Rbago, Gregorio ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

CONFERENCE PAPER; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIFE EXPECTANCY; NEPHROTOXICITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0343526822     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006271-00006     Document Type: Conference Paper

References (34)

1. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507-515.
2. Renlund DG, Gopinathan SK, Kfoury AG, Taylor DO. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment. Clin Transplant 1996; 10(pt 2): 136-139.
3. Taylor DO, Sharma RC, Kfoury AG, Renlund DG. Increased incidence of allograft rejection in stable heart transplant recipients after late conversion from mycophenolate mofetil to azathioprine. Clin Transplant 1999; 13: 296-299.
4. Dubrey SW, Holt DW, Banner N. Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels. Ther Drug Monit 1999; 21: 325-326.
5. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999; 18: 143-149.
6. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporine, FK506, and rapamycin on graft-vessel disease. Lancet 1991; 338: 1297-1298.
7. Morris RE, Meiser BM, Wu J, Shorthouse R, Wang J. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991; 23: 521-524.
8. Vu MD, Qi S, Xu D, et al. Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 1998; 66: 1575-1580.
9. Hosenpud JD, Bennett LE, et al. The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report - 1999. J Heart Lung Transplant 1999; 18: 611-626.
10. Brann WM, Bennett LE, Keck BM, Hosenpud JD. Morbidity, functional status, and immunosuppressive therapy after heart transplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. J Heart Lung Transplant 1998; 17: 374-382.
11. Woolfson RG, Neild GH. Cyclosporine nephrotoxicity following cardiac transplantation. Nephrol Dial Transplant 1997; 12: 2054-2056.
12. Tinawi M, Miller L, Bastani B. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 1997; 11: 1-8.
13. Ruggenenti P, Perico N, Amuchastegui CS, et al. Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporine. Am J Kidney Dis 1994; 24: 549-553.
14. Waser M, Maggiorini M, Binswanger U, et al. Irreversibility of cyclosporine-induced renal function impairment in heart transplant recipients. J Heart Lung Transplant 1993; 12: 846-850.
15. McGiffin DC, Kirklin JK, Naftel DC. Acute renal failure after heart transplantation and cyclosporine therapy. J Heart Transplant 1985; 4: 396-399.
16. Greenberg A, Egel JW, Thompson ME, et al. Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. Am J Kidney Dis 1987; 9: 12-22.
17. Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine-results at six months after transplantation. Transplantation 1999; 68: 663-671.
18. Zietse R, Balk AH, Dorpel MA, et al. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994; 14: 1-5.
19. Myers BD, Newton L, Boshkos C, et al. Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation 1988; 46: 694-703.
20. Myers BD, Sibley R, Newton L, et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 1988; 33: 590-600.
21. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62: 364-370.
22. Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40: 243-250.
23. Goldstein DJ, Zuech N, Sehgal V, et al. Cyclosporine-associated end-stage nephropathy after cardiac transplantation. Transplantation 1997; 63: 664-668.
24. Kuo PC, Luikart H, Busse-Henry S, et al. Clinical outcome of interval cadaveric renal transplantation in cardiac allograft recipients. Clin Transplant 1995; 9: 92-97.
25. Greenberg A, Thompson ME, Griffith BJ, et al. Cyclosporine nephrotoxicity in cardiac allograft patients-a seven-year follow-up. Transplantation 1990; 50: 589-593.
26. Van Gelder T, Balk AHMM, Zietse R, et al. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant 1998; 13: 2322-2326.
27. Hornberger J, Best J, Geppert J, McClellan M. Risks and costs of end-stage renal disease after heart transplantation. Transplantation 1998; 66: 1763-1770.
28. Seghal V et al. Progressive renal insufficiency following cardiac transplantation: cyclosporine. Am J Kidney Dis 1995; 26: 193-201.
29. Wagoner LE. Management of the cardiac transplant recipient: roles of the transplant cardiologist and primary care physician. Am J Med Sci 1997; 314: 173-184.
30. Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997; 12: 375-381.
31. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336-345.
32. Mihatsch MJ, Kyo M, Morozumi K, et al. The side-effects of cyclosporine-A and tacrolimus. Clin Nephrol 1998; 49: 356-363.
33. Grinyó JM. Progress with cyclosporine-sparing regimens. Transplant Proc 1999; 31(suppl 8A): 11S-16S.
34. Danovitch GM. Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients. Transplant Proc 1999; 31(suppl 8A): 2S-6S.